Understand your diagnosis, educate yourself, connect with communities, advocate for yourself, raise awareness, know your rights and collaborate.
https://www.curetoday.com/view/i-have-lynch-syndrome-the-evolution-from-patient-to-advocate
Author: Lynch Syndrome Ireland
Dominantly inherited micro-satellite instable cancer – the four Lynch syndromes – an EHTG, PLSD position statement
Improved survival following early diagnosis and treatment of MSI cancers of the colon, endometrium and ovary has led to carriers living on and contracting subsequent cancers in other organs. These have worse prognoses.
Tests for MSI have generally been optimised to demonstrate MSI colon cancers, but the different Lynch syndrome genes have different organ specific penetrance and expressivities. The prevalence of MSI in cancers in these other organs is not well studied, with respect to either how to test for MSI cancers in these organs or to estimate the frequency of MSI cancers. Identifying such MSI cancers would be of interest to select cases for immunotherapy tailored against MSI cancers.
The obvious next steps for clinical research on the MSH2 and MLH1 syndromes include determining the effects of immunotherapy for cancers with currently poor prognoses.
https://hccpjournal.biomedcentral.com/articles/10.1186/s13053-023-00263-3
Gene-Specific Considerations in Lynch Syndrome: MSH6
Gene-Specific Considerations in Lynch Syndrome: PMS2
Gene-Specific Considerations in Lynch Syndrome: EPCAM
Gene-Specific Considerations in Lynch Syndrome: MSH2
Gene-Specific Considerations in Lynch Syndrome -MLH1
NCCN guidelines
Genetic/Familial High-Risk Assessment: Colorectal
- NCCN Guidelines Version 1.2023
– Adenomatous Polyposis Testing Criteria
– Attenuated Familial Adenomatous Polyposis
– Colonic Adenomatous Polyposis of Unknown Etiology
– Familial Adenomatous Polyposis
– Juvenile Polyposis Syndrome
– Lynch Syndrome
– MUTYH-Associated Polyposis
– Peutz-Jeghers Syndrome
– Serrated Polyposis Syndrome
Lynch Syndrome Ireland 